An Open-label Pilot Study to Determine the Safety and Efficacy of Fixed-dose Glecaprevir and Pibrentasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms REHANNA
- 05 Sep 2019 Planned End Date changed from 1 Aug 2020 to 1 May 2020.
- 05 Sep 2019 Planned primary completion date changed from 25 Aug 2019 to 1 May 2020.
- 05 Sep 2019 Status changed from recruiting to active, no longer recruiting.